Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma
10.3760/cma.j.cn121090-20241201-00518
- VernacularTitle:蛋白酶体抑制剂纳米靶向给药治疗多发性骨髓瘤研究进展
- Author:
Yuxin LIN
1
;
Duohui JING
;
Jianqing MI
Author Information
1. 上海交通大学医学院附属瑞金医院血液科，上海血液学研究所，组学与疾病全国重点实验室，国家转化医学研究中心，上海 200025
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(8):779-784
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, proteasome inhibitors have been widely applied in the treatment of multiple myeloma (MM), demonstrating significant therapeutic value. However, these drugs face numerous clinical challenges, such as short circulation half-life, poor water solubility, patient resistance, and severe adverse events. Nanoparticles for targeted drug delivery, with unique advantages, have shown promise as an effective solution to these issues. This paper reviews the mechanisms of nanotargeted drug delivery for proteasome inhibitors and the progress of their use in MM treatment both domestically and internationally, aiming to provide a reference for researchers in related fields.
